Physicians' Academy for Cardiovascular Education

Kidney disease & CVD

Follow the news, literature, and elearning on new developments in the management of Kidney disease and CVD

Which patients benefit from potassium binders?

10' education - Feb. 15, 2022 - Kevin Damman, MD, PhD

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Interpreting findings of studies on a non-steroidal MRA in T2DM and CKD

10' education - Nov. 9, 2021 - Prof. George Bakris, MD, prof. Betram Pitt, MD and prof. Rajiv Agarwal, MD

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

Introduction on tackling cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia

3' education - Nov. 17, 2019 - Sripal Bangalore, MD, New york - AHA 2019, Philadelphia

Influence of MRA use on benefit of SGLT2i in HFpEF

Literature - Apr. 28, 2022 - Ferreira JP, et al. - J Am Coll Cardiol. 2022

A secondary analysis of the EMPEROR-Preserved shows that empagliflozin reduces the primary outcome regardless of background mineralocorticoid receptor antagonists (MRA) therapy. Reduction of total HF hospitalization was more pronounced in MRA nonusers.

Bempedoic acid lowers LDL-c safely in subgroups of patients

News - Apr. 19, 2022

ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.

CV and kidney benefits of nonsteroidal MRA irrespective of ASCVD history

News - Apr. 11, 2022

ACC 2022 A subanalysis of FIDELITY shows that the nonsteroidal MRA finerenone resulted in CV and kidney benefits in both primary and secondary prevention groups in a patient population with CKD and T2DM.

Early stop of phase III trial evaluating SGLT2 inhibitor in CKD

News - Mar. 21, 2022

The Independent Data Monitoring Committee of the EMPA-KIDNEY trial has recommended to stop the trial early due to positive efficacy. The EMPA-KIDNEY trial evaluates the effect of empagliflozin in adults with CKD.

ARNI may reduce adverse kidney outcomes in HF patients

Literature - Mar. 15, 2022 - Mc Causland FR, et al. - Eur J Heart Fail 2022

A pooled analysis of PARADIGM-HF and PARAGON-HF shows that treatment with sacubitril/valsartan results in a reduction of the primary composite renal endpoint and slows eGFR decline compared to RAS inhibition.

E-learning 3 Things a cardiologist needs to know about potassium binders

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Watch the videos in this series by a faculty of heart failure experts from Groningen, The Netherlands, and learn what a cardiologist needs to know about potassium binding!

Which patients benefit from potassium binders?

10' education - Feb. 15, 2022 - Kevin Damman, MD, PhD
Kevin Damman outlines the problem of hyperkalemia with regard to RAASi use. Moreover, he discusses which patients are at risk of hyperkalemia and could benefit from potassium binders.

Kevin Damman outlines the problem of hyperkalemia with regard to RAASi use. Moreover, he discusses which patients are at risk of hyperkalemia and could benefit from potassium binders. With question to test your knowledge.

Incidence of new-onset diabetes reduced by SGLT2 inhibitor

Literature - Feb. 9, 2022 - Rossing P, et al. - Lancet Diabetes Endocrinol. 2022

Treatment with the SGLT2 inhibitor dapagliflozin resulted in a reduction of new-onset T2DM in patients with CKD and HF, in a pooled analysis using data of the DAPA-CKD and DAPA-HF trials.

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD
Three experts talk about findings from clinical trials with the non-steroidal MRA finerenone in patients with CKD and T2DM and how to implement these findings in daily clinical practice.

Three experts talk about findings from clinical trials with the non-steroidal MRA finerenone in patients with CKD and T2DM and how to implement these findings in daily clinical practice.

Subclinical multi-organ affection after recovery from mild to moderate COVID-19

Literature - Jan. 20, 2022 - Petersen EL, et al. - Eur Heart J 2021
A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

New eGFR equations without race

News - Nov. 23, 2021

The use of race in equations to estimate GFR is a subject of discussion. This study developed new eGFR equations that do not include race and compared the performance of current and new eGFR equations.

Interpreting findings of studies on a non-steroidal MRA in T2DM and CKD

10' education - Nov. 9, 2021 - Prof. George Bakris, MD, prof. Betram Pitt, MD and prof. Rajiv Agarwal, MD
The findings from the FIGARO-DKD trial and the FIDELITY analysis with finerenone in T2DM patients across a broad spectrum of kidney disease were presented at the ESC 2021. What is the impact of these results on clinical practice?

The findings from the FIGARO-DKD trial and the FIDELITY analysis with finerenone in T2DM patients across a broad spectrum of kidney disease were presented at the ESC 2021. What is the impact of these results on clinical practice?